Is your child at risk of blindness? We are recruiting shortsighted children in Ireland to participate in MOSAIC, the first European drug trial designed to control myopia development! Please direct message or email us at email@example.com if interested! #Mosaictrial #myopia
— ABOUT CERI—
What we do
The Centre for Eye Research Ireland (CERI) is an ophthalmic research centre with cutting edge facilities specialising in:
Eye Health, Digital Health and Vision Enhancement
Technology Development &Transfer, Commercial Innovation and Intellectual Property creation
Fully customisable and integrated Clinical Trial solutions and implementation
The CERI team has designed and delivered more than 10 Clinical Trials, including COMPASS, the Polysoft Comfort Trial and the Macular Pigment in Glaucoma Trial. We have also provided consultancy services to a number of collaborative studies (TILDA, CARDS, CREST). Two clinical trials are currently underway funded by the HRB/MRCG, Fighting Blindness and Alliance Pharma, focused on novel interventions for glaucoma and myopia.
ESHI is a dedicated national translational research platform, uniquely based on collaboration between TU Dublin, the Health Service Executive (HSE) and Dublin City Council (DCC), thereby positioning CERI to achieve maximal impact on health policy and practice.
Our infrastructure comprises two cutting edge Vision and Eye Health labs allowing us to engage in a wide array of basic, applied and clinical research. The broader facilities within ESHI allow CERI to expand its range of research to Nutrition, Health Informatics, Human Biomonitoring, Bioengineering and Technology translation.
Glaucoma, which is a progressive optic neuropathy, is the second leading cause of global blindness. Current therapeutic options are limited, and typically fail to arrest disease progression for the majority of glaucoma patients. ENIGMA trial is designed to determine the impact of dietary supplementation on vision and quality of life including symptoms of glare among glaucoma subjects.
Children using atropine for reduction of myopia progression
The primary objective of CHAMP is to evaluate the safety & efficacy of 2 concentrations of atropine sulfate ophthalmic solution (0.01% & 0.02%) compared to placebo (vehicle) for the reduction of progression of myopia over a 3-year treatment period.
Priority Research Areas
— OUR PRIORITIES —
— PROJECTS —
By 2050, it is expected that 5 billion people will be affected with myopia (more than half the global population will need glasses and eye care), with up to one-fifth of them (1 billion) at a significantly increased risk of blindness. In parts of Asia, more than 90% of young people are affected, while in Ireland, Europe and the USA, it has doubled to close to 50% of people affected by the time they leave education.
Our team at CERI is working to find a means to control and prevent myopia (short-sightedness) in children.
Our research is broad ranging, and includes:
- Schools projects to engage children, teachers and parents in our myopia research
- Clinical trials to investigate the potential of new therapies to slow down the progression of myopia
- Novel technology development projects to determine peoples risk of developing myopia, and biomedical devices for the prevention and optimal control of myopia.
Several nutrients have been used in an attempt to treat or prevent the development of eye diseases. Vitamins A, C, D and E, zinc, lutein, zeaxanthin and meso-zeaxanthin, omega-3 fatty acids all play a role in eye health. Research suggests that nutrients with antioxidant and anti-inflammatory properties can reduce the risk of eye disease.
CERI is conducting research to evaluate the role of nutrition and nutraceuticals for prevention of eye disease and enhancement of vision for individuals with vision problems or those with critical visual demands, such as elite sports athletes.
Our team at CERI is working on numerous pipeline projects for blindness prevention.
Our team is working with Polymer Sciences on the development of a new (cost-effective) contact lens applicable to emerging markets including India, China, Africa, and Eastern Europe, where the costs of current contact lenses are prohibitive. The Polysoft Comfort Trial comprised the first human eye clinical trial of the new device.
Glaucoma is a progressive disease that can cause blindness and have a significant impact on quality of life If not carefully controlled. The only current therapy available for glaucoma is to reduce the pressure in the eye using eye drops or surgery. Very often, the condition continues to progress, however, and many people begin to suffers symptoms such as glare that can affect the ability to drive at night for example.
The modern diet is very deficient in nutrients essential for optimal eye health and good quality vision. A pigment in the eye, called macular pigment, provides essential protection against oxidative stress and inflammation in the eye, and also serves to optimise vision and alleviate the problem of glare which is now increasingly common in our visually complex world.
CERI team is working on the development of a novel nutritional therapy that can halt the progression of the disease, and improve the quality of life of people with glaucoma. We are now recruiting glaucoma patients for a clinical trial where we will supplement patients over a 2 year period and measure the impact on their disease and ocular function. As the 2nd leading cause of blindness in Ireland, this new therapy has the capacity to positively influence the lives of many.
38% of the population regularly experience one ore more dry eye symptoms. 66% of patients have tried 3 or more artificial tears for 2 or more years prior to the eye exam and report they do not help as hoped.
The symptoms of dry eye can be aggravated by prolonged visual efforts such as reading, working on the computer and driving. Environmental factors such as low humidity, air travel, heating or air conditioning and contact lens wear can also contribute or worsen dry eye.
Targeted nutritional supplementation can effectively fight against ocular surface inflammation, which is the key mechanism of ocular surface injury, as both the cause and consequence of cell damage.
There is no current therapeutic approach to the control and prevention of myopia, which is expected to affect one in three people worldwide by 2020, and represents the only major cause of blindness that is untreatable.
CHAMP and MOSAIC are the first European trials to explore the efficacy and safety of atropine for myopia prevention in a Caucasian population.
Targeted nutrition can benefit eye health and visual performance. We are conducting research to evaluate the role of nutrition and nutraceuticals for prevention of eye disease and enhancement of vision for individuals with vision problems or those with critical visual demands, such as elite sports athletes.
Glaucoma is a progressive disease that can cause blindness and a significant impact on quality of life If not carefully controlled. We are currently evaluating a novel nutritional therapy for glaucoma.